Jun12682
Based on 1 publication(s) in Google Scholar
Jun12682 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor, with a Ki value of 37.7 nM and an EC50 value of 1.1 μM in the FlipGFP PLpro assay. Jun12682 has efficacy in hindering PLpro both deubiquitination and deISGylation, with Ki values of 63.5 and 38.5 nM, respectively. Jun12682 exhibits resistance in multiple PLpro mutant strains, and its enzymatic activity is comparable to that of the wild-type. Jun12682 can be used for the study of the SARS-CoV-2.
For research use only. We do not sell to patients.
- Purity: 99.60%
- Formula: C29H36N6O2
- Molecular Weight:500.64
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Jun12682
More
Biological Activity
Jun12682 inhibits the replication of the SARS-CoV-2 virus, with EC50 values of 0.42 and 0.51 μM in the icSARS-CoV-2-nLuc reporter virus and plaque assays, respectively[1].
Jun12682 is highly stable in the human microsomes (T1/2 = 131.9 min, CLint (mic) = 10.5 μL/min/mg)[1].
Jun12682 shows consistent antiviral activity against SARS-CoV-2 delta and omicron variants and Nirmatrelvir (HY-138687)-resistant strains (rNsp5-S144M, rNsp5-L50F/E166V and rNsp5-L50F/E166A/L167F) in Caco-2 cells (EC50: 0.44-2.02 μM)[1][2].
Jun12682 has no inhibitory activity on the related human proteases USP7 and USP14 and cytochrome P450 (CYP450) enzymes, including CYP1A2, 2C9, 2C19, 2D6 and 3A-M (IC50 > 50.0 mM)[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:lethal SARS-CoV-2 model established in young BALB/c mice (9 to 12 weeks old)[1]
-
Dosage:125 and 250 mg/kg for 3 days and 500 mg/kg for 5 days
-
Administration:Oral administration (p.o.), twice daily for 3 or 5 days
-
Result:Exhibited reduced weight loss, resulting in a significantly improved survival rate and the three-day treatment of 250 mg/kg dose conferred even better protection.
Had statistically lower lung viral titers and considerably decreased viral antigen staining levels with a few sporadic positive cells.
Significantly reduced the viral N gene level and the expression of multiple inflammatory cytokines, including IFN-β, IL-1β, IL-6, and CXCL10 (36).
Chemical Information
-
Appearance Solid
-
Molecular Weight 500.64
-
Formula C29H36N6O2
-
Color White to off-white
-
SMILES
CC1=CC=C(C=C1C(N[C@@H](C2=CC(C3=CN(C)N=C3)=CC(C4=NN(CC)C=C4)=C2)C)=O)OCCN(C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
PLoS Pathog
Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. [Abstract]2025 Sep 5;21(9):e1013468. PMID: 40911642
Solvent & Solubility
DMSO : 100 mg/mL (199.74 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tan B, et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science. 2024 Mar 29;383(6690):1434-1440. [Content Brief]
[2]. Yang M, Kim M, Zhan P. Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice. Acta Pharm Sin B. 2024 Sep;14(9):4189-4192. [Content Brief]
[3]. Yang M, Kim M, Zhan P. Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice. Acta Pharm Sin B. 2024 Sep;14(9):4189-4192. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9974 mL | 9.9872 mL | 19.9744 mL | 49.9361 mL |
| 5 mM | 0.3995 mL | 1.9974 mL | 3.9949 mL | 9.9872 mL | |
| 10 mM | 0.1997 mL | 0.9987 mL | 1.9974 mL | 4.9936 mL | |
| 15 mM | 0.1332 mL | 0.6658 mL | 1.3316 mL | 3.3291 mL | |
| 20 mM | 0.0999 mL | 0.4994 mL | 0.9987 mL | 2.4968 mL | |
| 25 mM | 0.0799 mL | 0.3995 mL | 0.7990 mL | 1.9974 mL | |
| 30 mM | 0.0666 mL | 0.3329 mL | 0.6658 mL | 1.6645 mL | |
| 40 mM | 0.0499 mL | 0.2497 mL | 0.4994 mL | 1.2484 mL | |
| 50 mM | 0.0399 mL | 0.1997 mL | 0.3995 mL | 0.9987 mL | |
| 60 mM | 0.0333 mL | 0.1665 mL | 0.3329 mL | 0.8323 mL | |
| 80 mM | 0.0250 mL | 0.1248 mL | 0.2497 mL | 0.6242 mL | |
| 100 mM | 0.0200 mL | 0.0999 mL | 0.1997 mL | 0.4994 mL |
Jun12682 Related Classifications
HY-157403 Related Classifications
Powered by Bioz